These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 30806710)

  • 1. Janus kinases to jakinibs: from basic insights to clinical practice.
    Gadina M; Le MT; Schwartz DM; Silvennoinen O; Nakayamada S; Yamaoka K; O'Shea JJ
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i4-i16. PubMed ID: 30806710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK inhibitors: Ten years after.
    Spinelli FR; Meylan F; O'Shea JJ; Gadina M
    Eur J Immunol; 2021 Jul; 51(7):1615-1627. PubMed ID: 33930196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
    Howell MD; Kuo FI; Smith PA
    Front Immunol; 2019; 10():2342. PubMed ID: 31649667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.
    Schwartz DM; Bonelli M; Gadina M; O'Shea JJ
    Nat Rev Rheumatol; 2016 Jan; 12(1):25-36. PubMed ID: 26633291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.
    Schwartz DM; Kanno Y; Villarino A; Ward M; Gadina M; O'Shea JJ
    Nat Rev Drug Discov; 2017 Dec; 16(12):843-862. PubMed ID: 29104284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?
    Liu C; Kieltyka J; Fleischmann R; Gadina M; O'Shea JJ
    Arthritis Rheumatol; 2021 Dec; 73(12):2166-2178. PubMed ID: 34180156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The next step in the treatment of immune diseases: jakinibs, inhibitors of the intracellular Janus kinase].
    van de Laar MAFJ; Hoentjen F; Thio HB
    Ned Tijdschr Geneeskd; 2019 Aug; 163():. PubMed ID: 31433146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK inhibitors: Is specificity at all relevant?
    Gadina M
    Semin Arthritis Rheum; 2024 Feb; 64S():152327. PubMed ID: 38007359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.
    Kontzias A; Kotlyar A; Laurence A; Changelian P; O'Shea JJ
    Curr Opin Pharmacol; 2012 Aug; 12(4):464-70. PubMed ID: 22819198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
    Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
    J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK-STAT inhibitors for the treatment of immunomediated diseases.
    Serra López-Matencio JM; Morell Baladrón A; Castañeda S
    Med Clin (Barc); 2019 May; 152(9):353-360. PubMed ID: 30527218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
    Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
    Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in kinase inhibition: treating rheumatic diseases and beyond.
    Gadina M
    Curr Opin Rheumatol; 2014 Mar; 26(2):237-43. PubMed ID: 24419749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting cytokine signaling in autoimmunity: back to the future and beyond.
    Hirahara K; Schwartz D; Gadina M; Kanno Y; O'Shea JJ
    Curr Opin Immunol; 2016 Dec; 43():89-97. PubMed ID: 27821272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.
    Luo Y; Alexander M; Gadina M; O'Shea JJ; Meylan F; Schwartz DM
    J Allergy Clin Immunol; 2021 Oct; 148(4):911-925. PubMed ID: 34625141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
    Salas A; Hernandez-Rocha C; Duijvestein M; Faubion W; McGovern D; Vermeire S; Vetrano S; Vande Casteele N
    Nat Rev Gastroenterol Hepatol; 2020 Jun; 17(6):323-337. PubMed ID: 32203403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
    T Virtanen A; Haikarainen T; Raivola J; Silvennoinen O
    BioDrugs; 2019 Feb; 33(1):15-32. PubMed ID: 30701418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
    Bonelli M; Kerschbaumer A; Kastrati K; Ghoreschi K; Gadina M; Heinz LX; Smolen JS; Aletaha D; O'Shea J; Laurence A
    Ann Rheum Dis; 2024 Jan; 83(2):139-160. PubMed ID: 37923366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK inhibitors for the treatment of autoimmune and inflammatory diseases.
    Jamilloux Y; El Jammal T; Vuitton L; Gerfaud-Valentin M; Kerever S; Sève P
    Autoimmun Rev; 2019 Nov; 18(11):102390. PubMed ID: 31520803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus kinase inhibitors for rheumatoid arthritis.
    Yamaoka K
    Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.